ERBB2 and breast neoplasm: Thus, HER2-negative cancer may awake the silenced HER2 expression upon radiotherapy, and HER2-expressing breast CSCs are enriched in recurrent breast tumors (Figs. 1 and 2), which explains the potential clinical benefits of anti-HER2 therapy in originally HER2-negative breast cancer.